Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: Involvement of cell cycle arrest and inactivation of nuclear factor-κB

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 6, 2010, Pages 897-903

  Chen, Hua ^a   Sun, Bei ^a   Wang, Shuangjia ^a   Pan, Shangha ^a   Gao, Yue ^b   Bai, Xuewei ^a   Xue, Dongbo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cell cycle arrest; Dihydroartemisinin; Nuclear factor kappa B; Pancreatic neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE; DIHYDROQUINGHAOSU; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; HUMAN; INTERPHASE; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ARTEMISININS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERPHASE; NF-KAPPA B; PANCREATIC NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 77951651771     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-009-0731-0     Document Type: Article

References (45)

1. Aggarwal BB (2004) Nuclear factor-κB: the enemy within. Cancer Cell 6:203-208. doi:10.1016/j.ccr.2004.09.003
2. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D (2003) Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett 552(2-3):141-144. doi:10.1016/S0014-5793(03) 00905-0
3. Chen HH, Zhou HJ, Fang X (2003) Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 48:231-236. doi:10.1016/S1043-6618(03)00107- 5
4. Chen H, Sun B, Pan S, Jiang H, Sun X (2009) Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 20(2):131-140. doi:10.1097/CAD.0b013e3283212ade
5. Dai Y, Grant S (2004) Small molecule inhibitors targeting cyclindependent kinases as anticancer agents. Curr Oncol Rep 6:123-130. doi:10.1007/s11912-004- 0024-3
6. Derradji H, Baatout S (2003) Apoptosis: a mechanism of cell suicide. In Vivo 17:185-192
7. Devault A, Cavadore JC, Fesquet D, Labbé JC, Lorca T, Picard A, Strausfeld U, Dorée M (1991) Concerted roles of cyclin A, cdc25+ mitotic inducer, and type 2A phosphatase in activating the cyclin B/cdc2 protein kinase at the G2/M phase transition. Cold Spring Harb Symp Quant Biol 56:503-513. doi:10.1101/SQB.1991.056.01.057
8. EVerth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES (2002) Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J Mol Med 80(4):233-242. doi:10.1007/s00109-001-0300-8
9. EVerth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO (2003) Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64(2):382-394. doi:0026-895X/03/6402-382-394
10. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C, Chiao PJ (2003) Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 9:346-354
11. Fujita T, Felix K, Pinkaew D, Hutadilok-Towatanab N, Liu Z, Fujise K (2008) Human fortilin is a molecular target of dihydroartemisinin. FEBS Lett 582:1055-1060. doi:10.1016/j.febslet.2008.02.055
12. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM (2002) Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123:2052-2063. doi:10.1053/gast.2002.37075
13. Hartwell LH, Kastan MB (1994) Cell cycle control and cancer. Science 266:1821-1828. doi:10.1126/science.7997877
14. Hou J, Wang D, Zhang R, Wang H (2008) Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14:5519-5530. doi:10.1158/1078-0432.CCR-08-0197
15. Huang XJ, Ma ZQ, Zhang WP, Lu YB, Wei EQ (2007) Dihydroartemisinin exerts cytotoxic eVects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol 59:849-856. doi:10.1211/jpp.59.6.0011
16. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MH (2005) Cancer statistics, 2005. CA Cancer J Clin 55(1):10-30. doi:10.3322/canjclin.55.1.10
17. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ (2007) Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 28:1045-1056. doi:10.1111/j.1745-7254.2007.00612.x
18. Karin M (2006) Nuclear factor-κB in cancer development and progression. Nature 441:431-436. doi:10.1038/nature04870
19. Karin M, Greten FR (2005) NF-κB: linking inXammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759. doi:10.1038/nri1703
20. Kim SJ, Kim MS, Lee JW, Lee CH, Yoo H, Shin SH, Park MJ, Lee SH (2006) Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J Cancer Res Clin Oncol 132:129-135. doi:10.1007/s00432-005-0052-x
21. Kruidering M, Evan GI (2000) Caspase-8 in apoptosis: the beginning of "the end"? IUBMB Life 50:85-90. doi:10.1080/713803693
22. Li D, Xie K, WolV R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049-1057. doi:10.1016/S0140-6736(04)15841-8
23. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM (2003) Mitogenic and antiapoptotic role of constitutive NF-κB/ Rel activity in pancreatic cancer. Int J Cancer 105:735-746. doi:10.1002/ijc.11081
24. McDonald ER, El-Deiry WS (2000) Cell cycle control as a basis for cancer drug development. Int J Oncol 16:871-886
25. Mu D, Zhang W, Chu D, Liu T, Xie Y, Fu E, Jin F (2008) The role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancer PC-14 cells. Cancer Chemother Pharmacol 61:639-645. doi:10.1007/s00280-007-0517-5
26. Nam W, Tak J, Ryu JK, Jung M, Yook JI, Kim HJ, Cha IH (2007) EVects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck 29:335-340. doi:10.1002/hed.20524
27. Owa T, Yoshino H, Yoshimatsu K, Nagasu T (2001) Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 8:1487-1503
28. Sherr CJ (1996) Cancer cell cycles. Science 274:1672-1677. doi:10.1126/science.274.5293.1672
29. Sherr CJ (2004) Principles of tumor suppression. Cell 116:235-246. doi:10.1016/S0092-8674(03)01075-4
30. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512
31. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclindependent kinases. Genes Dev 18:2699-2711. doi:10.1101/gad.1256504
32. Siedle B, Garcia-Pineres AJ, Murillo R, Schulte-Monting J, Castro V, Rungeler P, Klaas CA, Da Costa FB, Kisiel W, Merfort I (2004) Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem 47:6042-6054. doi:10.1021/jm049937r
33. Singh NP, Lai H (2001) Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70:49-56. doi:10.1016/S0024-3205(01)01372-8
34. Singh NP, Lai HC (2004) Artemisinin induces apoptosis in human cancer cells. Anticancer Res 24:2277-2280
35. Singh NP, Lai HC (2005) Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. Anticancer Res 25:4325-4331
36. Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27-36. doi:10.1016/S1470-2045(03)01321-4
37. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM (1996) Suppression of TNF-induced apoptosis by NF-κB. Science 274:787-789. doi:10.1126/science.274.5288.787
38. van den Heuvel S, Harlow E (1993) Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262:2050-2054. doi:10.1126/science. 8266103
39. Vermeulen K, Berneman ZN, Van Bockstaele DR (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36:165-175
40. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999) The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancre Res 5:119-127
41. Wang J, Guo Y, Zhang BC, Chen ZT, Gao JF (2007) Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. Pharmacology 80:207-218. doi:10.1159/000104418
42. Wu XH, Zhou HJ, Lee J (2006) Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. Anticancer Drugs 17:839-848. doi:10.1097/01.cad.0000224443.85834.32
43. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K (2004) NF-κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 108:181-188. doi:10.1002/ijc.11562
44. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inXammation and cancer. J Clin Invest 107:135-142. doi:10.1172/JCI11914
45. Yebra M, Filardo EJ, Bayna EM, Kawahara E, Becker JC, Cheresh DA (1995) Induction of carcinoma cell migration on vitronectin by NF-κB-dependent gene expression. Mol Biol Cell 6:841-850